



FINANCIAL TEAR SHEET

CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life- improving drugs. For more than 30 years, we’ve been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in ove countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug develop process.

We help change people’s lives for the better every single day. It’s what we are passionate about.

STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$88.16
Change (%)	▼ 0.28 (0.32%)
Volume	201,076
52 Week Low	\$61.94
Market Cap	\$5,641,670,115
Rolling EPS	1.52
PE Ratio	58.1184
Shares Outstanding	63,790,933
Data as of 04/19/18 4:00 p.m. ET	



NEWS & EVENTS

Date	Title
------	-------

Date	Title
------	-------

04/12/18	PRA Health Sciences to Report First Quarter 2018 Earnings
03/14/18	PRA Health Sciences Receives CRO Leadership Award
03/06/18	PRA Health Sciences Named Best CRO in Asia

04/26/18	Q1 2018 PRA Health Sciences 9:00 a.m. ET
	Inc Earnings Conference Call

SEC FILINGS

Filing Date	Form
04/19/18	8-K
02/22/18	10-K
02/21/18	8-K
02/14/18	SC 13G

BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Alexander G. Dickinson	Director
Linda S. Grais, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)